Porter Derrell Form 4 February 19, 2019

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

if no longer subject to Section 16. Form 4 or

**SECURITIES** Form 5 obligations

may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

(Last)

(City)

1. Name and Address of Reporting Person \* Porter Derrell

Symbol

(Middle)

(Zip)

2. Issuer Name and Ticker or Trading

Atara Biotherapeutics, Inc. [ATRA]

3. Date of Earliest Transaction (Month/Day/Year)

C/O ATARA BIOTHERAPEUTICS, 02/15/2019 INC., 611 GATEWAY **BOULEVARD, SUITE 900** 

(Street)

(State)

(First)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

5. Relationship of Reporting Person(s) to

(Check all applicable)

SVP, Head of Global Commercial

10% Owner

Other (specify

Issuer

below)

Director

\_X\_\_ Officer (give title

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

**SOUTH SAN** FRANCISCO, CA 94080

| (City)                               | (State) (Z                              | Zip) Table | I - Non-De                             | erivative S       | Securi                                  | ties Acq   | uired, Disposed o  | f, or Beneficial   | ly Owned  |
|--------------------------------------|---|------------|--|-------------------|---|------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | (Month/Day/Year) Execution Date, if any |            | 3.<br>Transactio<br>Code<br>(Instr. 8) | n(A) or Di<br>(D) | A) or Disposed of D) instr. 3, 4 and 5) |            | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|                                      |   |            | Code V                                 | Amount            | (A)<br>or<br>(D)                        | Price      | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                   |  |   |
| Common<br>Stock                      | 02/15/2019                              |            | M(1)                                   | 4,000             | A                                       | \$<br>14.3 | 27,597   | D  |   |
| Common<br>Stock                      | 02/15/2019                              |            | S(1)                                   | 5,909             | D                                       | \$ 40      | 21,688   | D  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: Porter Derrell - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |         | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  |
|---|---|---|---|---|---------|--|-----------------|---|--|
|   |   |   |   | Code V  | (A) (D) | Date<br>Exercisable                                      | Expiration Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |
| Employee<br>Stock<br>Option<br>(Right to<br>Buy)    | \$ 14.3   | 02/15/2019                              |   | M <u>(1)</u>  | 4,000   | (2)  | 05/10/2024      | Common<br>Stock   | 4,000                                  |

## **Reporting Owners**

| Reporting Owner Name / Address | Kelationsinps |
|--------------------------------|---------------|
|--------------------------------|---------------|

Director

10% Owner

Officer

Porter Derrell C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080

SVP, Head of Global Commercial

Other

## **Signatures**

/s/ David Tucker, Attorney-in-Fact for Derrell
Porter

02/19/2019

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted November 9, 2018.
- (2) 25% of the shares subject to the option vest and become exercisable on May 10, 2018 and 1/48th of the shares subject to the stock option vest and become exercisable each full month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2